HISTORICAL FACTS: Verve therapeutics - The Untold Story

A $1.3 Billion Reason to Buy Eli Lilly Stock Now

Eli Lilly has just acquired gene-editing company Verve Therapeutics.

Barchart · Jun 20, 2025

Goodbye Statins? New Gene Editing Therapy Slashes High Cholesterol

A new gene therapy targeting an enzyme involved in familial hypercholesterolemia slashes bad cholesterol in a small clinical trial.

Inverse · Nov 13, 2023

Stocks Slip on Higher Bond Yields and U.S. Shutdown Concerns

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is down -0.21%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.31%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.35%. Stocks this morning are mostly lower. Higher bond yields...

Barchart · Nov 13, 2023